Cronos Group (CRON) vs Orchestra BioMed (OBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Cronos Group (CRON) over the past year, gaining 45.3% versus a gain of 28.3%. Over five years, OBIO leads with a -33.3% price change compared with -34.9% for CRON. Cronos Group is the larger company by market cap ($1.11 billion vs $517.9 million), about 2.2 times the size, while Orchestra BioMed is growing revenue faster (+1169.2% vs +24.6%).
Cronos Group converts more of its revenue into profit, with a net margin of -6.4% versus -157.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRON | OBIO |
|---|---|---|
| Share price | $3.04 | $6.58 |
| Market cap | $1.11B | $517.88M |
| 1-day change | -1.30% | -6.00% |
| YTD return | +15.59% | +58.55% |
| 1-year return | +28.27% | +45.25% |
| 5-year return | -34.90% | -33.27% |
| P/E ratio (TTM) | 19.00 | — |
| EPS (TTM) | $0.16 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $146.59M | $33.48M |
| Revenue growth (YoY) | +24.63% | +1169.22% |
| Net income (latest FY) | $-9.45M | $-52.70M |
| Gross margin | 42.81% | 99.43% |
| Operating margin | -11.87% | -154.73% |
| Net margin | -6.44% | -157.40% |
| 52-week high | $3.91 | $7.83 |
| 52-week low | $2.35 | $3.46 |
| Distance from 52-week high | -22.25% | -15.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | -3.62% | +101.98% |
| Average volume | 1.07M | 420.19K |
| Shares outstanding | 366.47M | 78.70M |
| Employees | 610 | 86 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cronos Group is about 2.2 times larger than Orchestra BioMed by market value ($1.11B vs $517.88M).
- OBIO has outperformed CRON by 17.0 percentage points over the past year.
- Cronos Group is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -157.4 cents for Orchestra BioMed.
- Orchestra BioMed grew revenue faster in its latest fiscal year (+1169.22% vs +24.63%).
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Health Care · Medicinal Chemicals and Botanical Products · 610 employees
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
CRON vs OBIO FAQ
Which is bigger, Cronos Group or Orchestra BioMed?
Cronos Group (CRON) is larger, with a market capitalization of $1.11B compared with $517.88M for Orchestra BioMed (OBIO).
Which stock has performed better over the past year, CRON or OBIO?
OBIO returned +45.25% over the past 12 months, compared with +28.27% for CRON (price return, excluding dividends). Past performance does not predict future results.
Are Cronos Group and Orchestra BioMed in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.